No Data
Enlightenment Pharmaceutical: Report for the third quarter of 2024
Express News | tus-pharmaceutical group: The company's controlling shareholder's shares may be auctioned judicially, and the company's controlling rights may change.
Express News | tus-pharmaceutical group: Change in company's controlling ownership may occur.
tus-pharmaceutical group (000590.SZ): a net loss of 28.4545 million yuan in the first three quarters.
On October 29th, Gelonhui reported that Tus-Pharmaceutical Group (000590.SZ) announced its third quarter report for 2024, with the company achieving revenue of 0.216 billion yuan for the first three quarters, a year-on-year decrease of 21.26%; net income attributable to shareholders of the listed company was -28.4545 million yuan; net income attributable to shareholders of the listed company excluding non-recurring gains and losses was -31.8838 million yuan; and basic earnings per share was -0.1188 yuan.
Tus-pharmaceutical group (000590.SZ): guangdong Xiantong Pharma currently has no products for the treatment of dengue fever.
According to the investor interaction platform, tus-pharmaceutical group (000590.SZ) stated that its wholly-owned subsidiary, Guangdong Xiantong Pharmaceutical Co., Ltd. currently has no products for the treatment of dengue fever.
Express News | tus-pharmaceutical group: Received a refund of 42.405 million yuan from Ming Shi Pharmaceutical shareholder share transfer.
No Data
No Data